Ert Batten Brineura denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for ert batten brineura are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies Cerliponase Alfa (Brineura) as Duplicate Therapy

Cigna may issue a duplicate-therapy denial for cerliponase alfa (Brineura) — an enzyme replacement therapy for a specific form of Batten disease (CLN2, neuronal ceroid lipofuscinosis type 2) — when its records suggest another agent in the same therapeutic category is active on the account, or when an internal pharmacy edit flags the claim for clinical review. Given that Brineura is the only FDA-approved treatment of its kind for this ultra-rare condition, a duplicate-therapy flag almost certainly reflects a claims-system or administrative error rather than a genuine clinical duplication concern.

## Why This Denial Is Appealable

Brineura has no therapeutically equivalent approved alternative for CLN2. A duplicate-therapy determination, to be clinically valid, must identify a specific other agent that duplicates its mechanism and indication. If no such agent exists or is actually being dispensed, the denial premise is incorrect. This type of error is eminently correctable on appeal with straightforward documentation.

## Federal Appeal Framework

• Internal appeal: File within the deadline on your denial notice (typically 180 days for ACA-compliant plans; check the denial letter). Cigna must respond within 60 days for post-service or 30 days for pre-service standard review.
• Expedited appeal: Request within 72 hours when clinical urgency is established — required for a drug treating a rapidly progressive pediatric neurological condition.
• External review (ACA §2719 / ERISA §503): After exhausting internal appeal, file for independent external review within approximately four months. The IRO's decision is binding on Cigna.

## Appeal Process and Timeline

1. Request Cigna's written rationale identifying the specific "duplicate" agent it believes is on file. 2. Confirm with the dispensing specialty pharmacy and the prescriber's office that no other agent with overlapping indication is active. 3. Obtain a letter from the treating physician — typically a pediatric neurologist with expertise in neuronal ceroid lipofuscinoses — affirming that Brineura is the sole approved enzyme replacement therapy for CLN2 and that no duplication exists. 4. Attach the FDA prescribing label confirming the drug's unique indication. 5. Submit the internal appeal with all documentation and escalate promptly if denied, given the progressive nature of the disease.

## Documentation to Gather

• Confirmed CLN2 diagnosis: Genetic confirmation, enzyme activity results, and neurological assessment — as recorded in the chart.
• Treating physician letter: Attesting to the unique mechanism and indication of Brineura and the absence of a duplicate agent.
• FDA prescribing label: Demonstrating the drug's approved indication for CLN2 specifically.
• Pharmacy records: Confirming no therapeutically overlapping agent is currently dispensed.
• Disease-progression documentation: Chart notes reflecting neurological status and functional trajectory, supporting urgency.

## Criteria-Mapping Structure

Obtain Cigna's published coverage policy for cerliponase alfa. List each criterion. For each, document the specific chart entry or label citation that satisfies it. For the duplicate-therapy criterion specifically, document point-by-point why no duplication exists, referencing the FDA label's unique indication language. Present this as a numbered mapping in the appeal letter.